I had originally thought the trial design clever in EMD AML with RC110 as it potentially offered an opportunity to gather data on FTO and Cardio Protection (and not dependent on readiness of RC220) in clinic for an unmet need in a subgroup (and thereby overcoming the crowded trial space issue). I
This also meant access to less heavily pretreated patients possibly offering better/clearer data (attribution). Do you see issue in focusing on r/r AML patient group (data and clinical development)?
General Comments / Chat, page-8658
-
- There are more pages in this discussion • 3,296 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.51 |
Change
-0.015(0.98%) |
Mkt cap ! $257.4M |
Open | High | Low | Value | Volume |
$1.55 | $1.55 | $1.45 | $196.2K | 131.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 5495 | $1.49 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.51 | 500 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 648 | 1.505 |
1 | 648 | 1.490 |
1 | 5495 | 1.485 |
1 | 8000 | 1.480 |
1 | 10000 | 1.470 |
Price($) | Vol. | No. |
---|---|---|
1.535 | 5535 | 1 |
1.540 | 5274 | 2 |
1.545 | 1013 | 2 |
1.550 | 3121 | 2 |
1.565 | 5000 | 1 |
Last trade - 13.11pm 21/10/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
LGP
LITTLE GREEN PHARMA LTD
Paul Long, Chief Executive Officer
Paul Long
Chief Executive Officer
SPONSORED BY The Market Online